SCHEMBL30954089

SCHEMBL30954089

CCCN1CCOc2c1cc(Cl)c(F)c2C(=O)OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.36
AR P10275 1/20 0.35
HTR2C P28335 4/20 0.35
HTR4 Q13639 4/20 0.35
ADRA2C P18825 3/20 0.35
HTR1D P28221 3/20 0.35
ADRA1A P35348 3/20 0.35
HTR2B P41595 3/20 0.35
HTR3A P46098 3/20 0.35
CHRM5 P08912 2/20 0.35
CHRM3 P20309 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2A P08913 2/20 0.35
HTR2A P28223 2/20 0.35
DRD5 P21918 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
HTR1A P08908 1/20 0.35
SLC6A2 P23975 1/20 0.35
ADRA1D P25100 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27434153 1.00 ENPP2 (0.36) ENPP2ARHTR2CHTR4ADRA2C
SCHEMBL27434007 0.91 CHRM5 (0.38) ENPP2ARCHRM5CHRM3CHRM1
SCHEMBL30954142 0.91 CHRM5 (0.38) ENPP2ARCHRM5CHRM3CHRM1
SCHEMBL27434163 0.88 AR (0.36) ARHTR2CHTR4HTR3ACHRM5
SCHEMBL30954145 0.88 AR (0.36) ARHTR2CHTR4HTR3ACHRM5
SCHEMBL27433869 0.88 ENPP2 (0.37) ENPP2HTR2CHTR4ADRA2CHTR1D
SCHEMBL30954098 0.88 ENPP2 (0.37) ENPP2HTR2CHTR4ADRA2CHTR1D
SCHEMBL27434031 0.84 HTR4 (0.36) ENPP2ARHTR2CHTR4ADRA2C
SCHEMBL30954129 0.84 HTR4 (0.36) ENPP2ARHTR2CHTR4ADRA2C
SCHEMBL30954122 0.83 P2RX7 (0.36) ENPP2HTR2CHTR4ADRA2CHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed